Rates of liver retransplantation in the United States are declining in the era of direct-acting antiviral agents

被引：3
|
作者：
Cholankeril, G. [1 ]
Yoo, E. R. [2 ]
Hu, M. [3 ]
Gadiparthi, C. [1 ]
Khan, M. A. [1 ]
Perumpail, R. B. [4 ]
Bonham, C. A. [5 ]
Ahmed, A. [4 ]
机构：
[1] Univ Tennessee, Ctr Hlth Sci, Div Gastroenterol & Hepatol, Memphis, TN 38163 USA
[2] Univ Illinois, Coll Med, Dept Med, Chicago, IL USA
[3] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI 02912 USA
[4] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA
[5] Stanford Univ, Sch Med, Dept Surg, Div Abdominal Transplantat, Stanford, CA 94305 USA
来源：
JOURNAL OF VIRAL HEPATITIS | 2017年 / 24卷 / 12期
关键词：
direct-acting antiviral; hepatitis C virus; liver transplantation; retransplantation; HEPATITIS-C; INFECTION;
D O I：
10.1111/jvh.12750
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1194 / 1195
页数：2
相关论文
共 50 条
  • [21] Outcome of hepatitis C–related liver transplantation in direct-acting antiviral era
    Narendra S. Choudhary
    Neeraj Saraf
    Sanjiv Saigal
    Amit Rastogi
    Prashant Bhangui
    Srinivas Thiagrajan
    Arvinder S. Soin
    Indian Journal of Gastroenterology, 2020, 39 : 539 - 543
  • [22] Liver Transplantation for Hepatitis C Patients in the Era of Direct-Acting Antiviral Treatment
    Khan, Adeel
    Adams, Nathaniel
    Vachharajani, Neeta
    Dageforde, Leigh Anne
    Wellen, Jason
    Shenoy, Surendra
    Doyle, Majella
    Chapman, William
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 64 - 64
  • [23] Changing Population of Liver Transplant Recipients in the Era of Direct-acting Antiviral Therapy
    Xie, Chencheng
    Kuo, Yong-Fang
    Singal, Ashwani K.
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2020, 8 (03) : 262 - 266
  • [24] Hepatitis C remains the main etiology of hepatocellular carcinoma among liver transplant recipients in the United States in the direct-acting antiviral era
    Saberi, B.
    Hashim, D.
    Dinani, A.
    Asgharpour, A.
    Kushner, T.
    Tabrizian, P.
    Schwartz, M.
    Dieterich, D.
    Llovet, J. M.
    Boffetta, P.
    Friedman, S. L.
    Gurakar, A.
    TRANSPLANTATION, 2019, 103 (08) : 312 - 312
  • [25] The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population
    Ferrante, Nicole D.
    Newcomb, Craig W.
    Forde, Kimberly A.
    Leonard, Charles E.
    Torgersen, Jessie
    Linas, Benjamin P.
    Rowan, Sarah E.
    Wyles, David L.
    Kostman, Jay
    Trooskin, Stacey B.
    Lo Re, Vincent
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (09):
  • [26] LIVER CANCER Effect of HCV clearance with direct-acting antiviral agents on HCC
    Llovet, Josep M.
    Villanueva, Augusto
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2016, 13 (10) : 561 - +
  • [27] Therapy With Direct-Acting Antiviral Agents for Hepatitis C in Liver Transplant Recipients
    Nogueras Lopez, F.
    Lopez Garrido, A.
    Ortega Suazo, E. J.
    Vadillo Galles, F.
    Valverde Lopez, F.
    Espinosa Aguilar, M. D.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (02) : 631 - 633
  • [28] The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes
    Axelrod, D. A.
    Schnitzler, M. A.
    Alhamad, T.
    Gordon, F.
    Bloom, R. D.
    Hess, G. P.
    Xiao, H.
    Nazzal, M.
    Segev, D. L.
    Dharnidharka, V. R.
    Naik, A. S.
    Lam, N. N.
    Ouseph, R.
    Kasiske, B. L.
    Durand, C. M.
    Lentine, K. L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (10) : 2473 - 2482
  • [29] Cryoglobulinemic vasculitis in the era of direct-acting antiviral drug
    Saadoun, David
    Cacoub, Patrice
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (03)
  • [30] Prophylaxis of HCV reinfection and direct-acting antiviral agents during liver transplantation
    Tavio, Marcello
    Vivarelli, Marco
    Menzo, Stefano
    Gori, Andrea
    Grossi, Paolo Antonio
    Marigliano, Anna
    LIVER TRANSPLANTATION, 2015, 21 (10) : 1327 - 1329
12345